Breaking Immune Tolerance to ACVR2A: A Fully Human Antibody Strategy for Muscle and Metabolic Disease

Obesity therapies are becoming increasingly effective at reducing body weight. But weight loss alone may no longer define the next frontier of metabolic drug development. The emerging challenge is to improve the quality of weight loss by reducing adiposity while preserving, or potentially enhancing, lean muscle mass and metabolic function. This shift has brought renewed attention to pathways that connect skeletal muscle biology with systemic metabolism. Among them, activin receptor type IIA (ACVR2A; ActRIIA) is attracting particular interest as a therapeutic target in muscle and metabolic disease. As a key type II receptor in the TGF-β superfamily, ACVR2A integrates signals from multiple ligands involved in muscle growth, body composition, and metabolic regulation, making it both biologically compelling and immunologically challenging for fully human antibody discovery ^[1].

Figure 1. Representation of the structure of ACVR2A (ActRIIA) signaling pathway ^[2].

ACVR2A integrates signals from ligands that include Activin A and growth differentiation factor 8 (GDF8, or myostatin), tying the receptor to skeletal muscle growth, adipose biology, and systemic metabolic homeostasis. That combination makes it relevant across obesity, sarcopenia, muscle wasting, and broader metabolic disease.

The receptor also highlights a familiar obstacle, namely what happens when a therapeutically attractive human target is nearly indistinguishable from its mouse counterpart.

Why ACVR2A Is an Attractive Therapeutic Target

As a fundamental transmembrane serine/threonine kinase receptor, ACVR2A acts as a primary type II receptor for several prominent members of the TGF-β superfamily. Following specific ligand engagement at the cell surface, ACVR2A physically recruits and phosphorylates type I receptors such as ALK4 or ALK7. This active receptor complex then induces the intracellular phosphorylation of downstream effector proteins, specifically SMAD2 and SMAD3, ultimately culminating in highly targeted nuclear transcriptional responses. The precise physiological outcome of this complex signaling cascade remains highly dependent on the localized cellular environment.

Within skeletal muscle tissue, ACVR2A-associated signaling actively contributes to molecular pathways that severely restrict muscle growth and potently inhibit new myogenesis. Conversely, in peripheral adipose tissue, parallel downstream signaling networks profoundly influence lipid metabolism, cellular adipogenesis, and overall systemic energy homeostasis. Pharmacologically blocking this specific signaling axis may therefore offer a unique dual mechanism to optimize two clinically critical components of human body composition. This therapeutic approach could effectively reduce total fat mass while simultaneously promoting and preserving vital skeletal muscle hypertrophy. A therapy like this would carry implications well beyond obesity, extending into sarcopenia, cachexia, and other muscle-wasting conditions. As GLP-1 therapeutics redefine weight loss, the biopharma industry is pivoting to the next frontier: quality of weight loss and lean mass preservation.

Figure 2. Illustration of insulin, GLP-1, and activin/myostatin signaling in skeletal muscle, highlighting how bimagrumab promotes muscle hypertrophy by blocking activin receptor signaling and reducing muscle protein breakdown ^[3].

The Antibody Discovery Challenge of Extreme Target Homology

While ACVR2A is a highly validated therapeutic target, it presents a formidable roadblock for traditional antibody discovery. The extracellular domain of ACVR2A shares greater than 99% sequence identity between humans and mice. The predictable consequence is immune tolerance.

Figure 3. Sequence homology comparisons of human and mouse ACVR2A ^[4].

When an antigen closely mirrors an endogenous mouse protein, immunization tends to generate a muted response, and that weak response narrows antibody diversity while lowering the odds of recovering high-affinity binders against functionally important human epitopes. The problem grows sharper when selectivity is required, because ACVR2A and the closely related ACVR2B share overlapping ligand networks. Traditional hybridoma or standard transgenic mouse approaches consistently hit a dead end here, yielding either no antibodies, low-affinity binders, or clones lacking functional neutralization capacity. Rather than pushing against this ceiling through immunization tweaks alone, Cyagen chose to change the immunological starting point.

Breaking Immune Tolerance with the HUGO-Ab-eKO™ Platform

Cyagen built the HUGO-Ab-eKO^TM homologous knockout strategy on top of its HUGO-Ab^TM fully human antibody mouse platform. The logic is direct, since tolerance in this setting arises because the human antigen resembles an endogenous mouse protein, and removing that mouse protein should restore the immune system's ability to see the human target as foreign.

In the ACVR2A program, Acvr2a was deleted in the engineered mouse background before immunization with human ACVR2A protein. Antigen-specific B cells were isolated and subjected to single-cell sequencing to recover naturally paired heavy- and light-chain sequences. Selected antibodies then underwent binding, receptor-selectivity, functional, pharmacokinetic, and in vivo efficacy studies.

Figure 4. HUGO-Ab-eKO^TM homologous knockout antibody discovery workflow.

Identifying High-Affinity, Selective ACVR2A Antibodies

Two lead antibodies, A0009 IgG1 and A0040 IgG1, emerged from the discovery program. Surface plasmon resonance analysis showed concentration-dependent binding of both antibodies to ACVR2A-His across analyte concentrations from 15.63 to 250 nM, and both candidates reached sub-nanomolar affinity. Measured against the reference IgG1 used in the study, A0009 and A0040 also displayed improved binding and stronger selectivity for ACVR2A over ACVR2B.

Figure 5. SPR kinetic and affinity analysis of ACVR2A antibodies.

Selectivity carries real weight in this receptor family. ACVR2A and ACVR2B operate within related signaling networks, yet their biological roles are not interchangeable, so preferential inhibition of ACVR2A offers a more targeted approach than blocking both receptors at once. Affinity and selectivity alone, however, cannot confirm that an antibody actually shuts down receptor signaling, which is why functional testing came next.

Functional Blockade in Muscle and Adipose Signaling Systems

Two cell-based reporter systems were used to model distinct ACVR2A pathway contexts. The first reconstructed ACVR2A-ALK4-pSMAD2/3 signaling tied to skeletal muscle biology, and the second examined ACVR2A-ALK7-pSMAD2/3 signaling associated with adipocyte biology. Both pathways lead to pSMAD2/3-dependent activation of the SBE-LUC reporter gene. A0009 and A0040 suppressed reporter activity in a concentration-dependent manner across the two configurations. These data link biochemical binding to biological activity and confirm that the antibodies interfere with downstream signaling in both muscle- and metabolism-relevant contexts.

Figure 6. ACVR2A SBE-LUC reporter assays under different ligand conditions.

Favorable Pharmacokinetic Profiles In Vivo

The two leads were then profiled in wild-type C57BL/6N mice after a single 20 mg/kg dose. A0009 carried a half-life roughly 2.4-fold longer than the reference antibody, together with an approximately 1.8-fold higher maximum serum concentration (Cmax) and about threefold greater total systemic exposure (AUC). A0040 improved on the reference as well, showing a modest half-life gain, a roughly 1.8-fold higher Cmax, and about 2.5-fold higher AUC. These properties made both candidates strong choices for the body-composition and muscle-function studies that followed.

Figure 7. Serum pharmacokinetics of ACVR2A antibodies in C57BL/6N mice.

Effects on Fat Mass, Lean Mass, and Muscle Function

In a diet-induced obesity (DIO) mouse model, A0040 produced the strongest overall effects on body weight and fat mass among the candidates evaluated. Both antibodies also improved muscle-related body-composition endpoints relative to the comparator, though their profiles differed. A0040 combined lower body weight and fat mass with increased or preserved muscle mass, while A0009 drove particularly notable gains in the muscle component.

Figure 8. Effects of anti-ACVR2A antibodies on body composition in DIO mice.

Because a shift in body composition does not by itself prove functional benefit, muscle strength was assessed directly. Male CB-17 SCID mice received PBS, a reference antibody, A0040, or A0009 at 20 mg/kg once weekly for four weeks, and at endpoint both A0009 and A0040 significantly increased grip strength over PBS controls, whereas the reference antibody did not. Taken together, these results show that the lead antibodies moved both body-composition parameters and a functional muscle endpoint.

Figure 9. Grip-strength assessment following ACVR2A blockade in CB-17 SCID mice.

A Broader Strategy for Difficult Antibody Targets

The value of the ACVR2A program reaches past its two lead molecules. Highly conserved membrane proteins and receptors are often hard to drug because self-tolerance blunts immune recognition, and these results show how target-specific mouse engineering paired with a fully human antibody platform can reshape that landscape. Starting from a target with greater than 99% human and mouse homology, the HUGO-Ab-eKO^TM workflow yielded fully human antibodies with strong affinity, ACVR2A-over-ACVR2B selectivity, functional pathway blockade, favorable pharmacokinetics, and measurable in vivo activity.

The same integrated pipeline can carry a program from target-specific mouse engineering and antigen design through B-cell isolation, single-cell sequencing, SPR and cross-reactivity characterization, cell-based functional assays, pharmacokinetics, and disease-relevant in vivo studies. For programs constrained by immune tolerance, engineering the host around the biology of the target can widen the accessible epitope space and open new routes to viable antibodies.

👉 [Explore our HUGO-Ab-eKO™ Target-Knockout Antibody Discovery Platform]

From Difficult Target to Validated Antibody

For highly conserved therapeutic targets, pairing fully human antibody discovery with homologous knockout strategies may offer a cleaner path from target selection to functional validation. Cyagen's HUGO-Ab^TM and HUGO-Ab-eKO^TM platforms support that workflow from discovery through preclinical characterization, and established target programs can also supply existing antibody candidates for downstream evaluation and development.

👉 [Explore our HUGO-Ab™ Fully Human Antibody Discovery Platform]

👉 [Download our brochure to learn more about our fully human antibody discovery strategies]

Reference

[1] Lodberg A. Principles of the activin receptor signaling pathway and its inhibition. Cytokine Growth Factor Rev. 2021 Aug;60:1-17. doi: 10.1016/j.cytogfr.2021.04.001. Epub 2021 Apr 20. PMID: 33933900.

[2] Verzola D, Barisione C, Picciotto D, Garibotto G, Koppe L. Emerging role of myostatin and its inhibition in the setting of chronic kidney disease. Kidney Int. 2019 Mar;95(3):506-517. doi: 10.1016/j.kint.2018.10.010. Epub 2018 Dec 28. PMID: 30598193.

[3] Lisco G, De Tullio A, Disoteo OE, Dicorato P, Tortora A, De Geronimo V, Triggiani V. Targeting the activin/myostatin - actrii pathway to preserve skeletal muscle mass in obesity: mechanistic insights and therapeutic perspectives. Rev Endocr Metab Disord. 2026 Aug;27(4):763-780. doi: 10.1007/s11154-026-10033-w. Epub 2026 Apr 9. PMID: 41954678; PMCID: PMC13388822.

[4] Research Institute of Tsinghua, Pearl River Delta. ACVR2A - Activin A Receptor Type 2A [Internet]. RDDC: AI-Powered Variant Analysis Platform; 2023 [cited 2026 Aug 18]. Available from: https://rddc.tsinghua-gd.org/gene/92